Vincristine
- Atc Codes:L01CA02
- CAS Codes:2068-78-2#57-22-7
- PHARMGKB ID:2068-78-2#57-22-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Oncovin, Vincristin; Belgium: Vincrisin; Bulgaria: Cytocristin; Czech Republic: Vincristine; Denmark: Oncovin; Finland: Oncovin; France: Oncovin, Vincristine; Germany: Cellcristin, Vincristin; Greece: Oncovin, Vincristine; Hungary: Vincristin; Ireland: Vincristine; Italy: Oncovin, Vincristina; Latvia: Vincristin; Lithuania: Oncrivin, Vincristine; Luxembourg: Oncovin, Vincristine, Vincristinum; Netherlands: Vincristine; Poland: Oncovin, Vincristin; Portugal: Vincristina; Romania: Sindovin; Slovakia: Vincristin; Spain: Vincristina, Vincrisul; Sweden: Oncovin, Vincristine; UK: Vincristine.
North America
Canada: Vincristine; USA: Vincristine.
Latin America
Argentina: Vincristina; Brazil: Oncovin, Tecnocris, Vincizina, Vincristin; Mexico: Citomid, Crivosín, Oncovín, Vincristina.
Asia
Japan: Oncovin.
Drug combinations
Chemistry
Vincristine Sulfate: C~46~H~56~N~4~O~10~ H~2~SO~4~. Mw: 923.04. (1) Vincaleukoblastine, 22-oxo-, sulfate (1:1); (2) Leurocristine sulfate (1:1). CAS-2068-78-2; CAS-57-22-7 (vincristine)(1962).
Pharmacologic Category
Antineoplastic Agents; Plant Alkaloids and Other Natural Products. Vinca Alkaloid. (ATC-Code: L01CA02).
Mechanism of action
Binds to tubulin and inhibits microtubule formation, therefore arresting cell at metaphase by disrupting formation of mitotic spindle. May also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.
Therapeutic use
Treatment of leukemias, Hodgkin’s disease, non-Hodgkin lymphomas, Wilms’ tumor, neuroblastoma, rhabdomyosarcoma.
Pregnancy and lactiation implications
May cause fetal harm. Teratogenicity and embryolethality demonstrated in animals. Pregnancy should be avoided during therapy.
Unlabeled use
Contraindications
Hypersensitivity to vincristine or any component of the formulation. Patients with demyelinating form of Charcot-Marie-Tooth syndrome. Pregnancy.
Warnings and precautions
Hazardous agent. Constipation and/or paralytic ileus may occur. Alterations in mental status (depression, confusion, or insomnia) may occur. Neurologic effects may be additive with those of other neurotoxic agents and spinal cord irradiation. Respiratory effects (shortness of breath and bronchospasm) might occur (especially in combination with mitomycin C). Urinary tract disturbances may occur. Use with caution in hepatic impairment, pre-existing neuromuscular disease, and in the elderly. Not for intrathecal use (caused severe neurologic damage and/or death). For I.V. use only. Vincristine is a vesicant (avoid extravasation).